» Articles » PMID: 23474584

CD39 Modulates Hematopoietic Stem Cell Recruitment and Promotes Liver Regeneration in Mice and Humans After Partial Hepatectomy

Abstract

Objective: To study molecular mechanisms involved in hematopoietic stem cell (HSC) mobilization after liver resection and determine impacts on liver regeneration.

Background: Extracellular nucleotide-mediated cell signaling has been shown to boost liver regeneration. Ectonucleotidases of the CD39 family are expressed by bone marrow-derived cells, and purinergic mechanisms might also impact mobilization and functions of HSC after liver injury.

Methods: Partial hepatectomy was performed in C57BL/6 wild-type, Cd39 ectonucleotidase-null mice and in chimeric mice after transplantation of wild-type or Cd39-null bone marrow. Bone marrow-derived HSCs were purified by fluorescence-activated cell sorting and administered after hepatectomy. Chemotactic studies were performed to examine effects of purinergic receptor agonists and antagonists in vitro. Mobilization of human HSCs and expression of CD39 were examined and linked to the extent of resection and liver tests.

Results: Subsets of HSCs expressing Cd39 are preferentially mobilized after partial hepatectomy. Chemotactic responses of HSCs are increased by CD39-dependent adenosine triphosphate hydrolysis and adenosine signaling via A2A receptors in vitro. Mobilized Cd39 HSCs boost liver regeneration, potentially limiting interleukin 1β signaling. In clinical studies, mobilized human HSCs also express CD39 at high levels. Mobilization of HSCs correlates directly with the restoration of liver volume and function after partial hepatectomy.

Conclusions: We demonstrate CD39 to be a novel HSC marker that defines a functionally distinct stem cell subset in mice and humans. HSCs are mobilized after liver resection, limit inflammation, and boost regeneration in a CD39-dependent manner. These observations have implications for monitoring and indicate future therapeutic avenues.

Citing Articles

Inhibition of Vascular Endothelial Growth Factor Protects against the Development of Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Wild-Type but Not in CD39-Null Mice.

Knitter S, Duwe G, Beierle A, Pesthy S, Ritschl P, Hillebrandt K Cancers (Basel). 2022; 14(23).

PMID: 36497474 PMC: 9739893. DOI: 10.3390/cancers14235992.


Liver Regeneration and Cell Transplantation for End-Stage Liver Disease.

Li Y, Lu L, Cai X Biomolecules. 2021; 11(12).

PMID: 34944550 PMC: 8699389. DOI: 10.3390/biom11121907.


Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities.

Wang P, Jia J, Zhang D JHEP Rep. 2020; 2(6):100165.

PMID: 33103092 PMC: 7575885. DOI: 10.1016/j.jhepr.2020.100165.


Platelets Boost Recruitment of CD133 Bone Marrow Stem Cells to Endothelium and the Rodent Liver-The Role of P-Selectin/PSGL-1 Interactions.

Lehwald N, Duhme C, Pinchuk I, Kirchner J, Wieferich K, Schmelzle M Int J Mol Sci. 2020; 21(17).

PMID: 32899390 PMC: 7504029. DOI: 10.3390/ijms21176431.


Hilar en bloc resection for hilar cholangiocarcinoma in patients with limited liver capacities-preserving parts of liver segment 4.

Jonas S, Krenzien F, Atanasov G, Hau H, Gawlitza M, Moche M Eur Surg. 2018; 50(1):22-29.

PMID: 30459814 PMC: 6223732. DOI: 10.1007/s10353-017-0507-8.


References
1.
Enjyoji K, Sevigny J, Lin Y, Frenette P, Christie P, Esch 2nd J . Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med. 1999; 5(9):1010-7. DOI: 10.1038/12447. View

2.
Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M . Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells. 2005; 23(8):1105-12. DOI: 10.1634/stemcells.2004-0330. View

3.
Deaglio S, Dwyer K, Gao W, Friedman D, Usheva A, Erat A . Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204(6):1257-65. PMC: 2118603. DOI: 10.1084/jem.20062512. View

4.
Willenbring H, Bailey A, Foster M, Akkari Y, Dorrell C, Olson S . Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med. 2004; 10(7):744-8. DOI: 10.1038/nm1062. View

5.
Robson S, Sevigny J, Zimmermann H . The E-NTPDase family of ectonucleotidases: Structure function relationships and pathophysiological significance. Purinergic Signal. 2008; 2(2):409-30. PMC: 2254478. DOI: 10.1007/s11302-006-9003-5. View